Minimal vitrectomy for epiretinal membrane

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized controlled trial compares Minimal Vitrectomy Surgery (MVS) with conventional pars plana vitrectomy in adults with idiopathic epiretinal membrane. MVS seeks to preserve the posterior hyaloid and minimize vitreous removal while allowing direct membrane peeling, with limited localized vitrectomy only if residual floaters or fragments cannot be safely removed. Primary outcomes include change in visual acuity and cataract progression at 12 months, with secondary outcomes of macular thickness, ERM recurrence, and intraoperative complications. Participants are phakic adults with OCT-confirmed idiopathic ERM and clear media who undergo surgery and longitudinal follow-up at the enrolling center(s).

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years.
2. Diagnosis of idiopathic epiretinal membrane (ERM) confirmed by clinical examination and OCT imaging.
3. Clear ocular media allowing adequate fundus imaging.
4. Phakic eye.
5. Ability and willingness to provide written informed consent.

Exclusion Criteria:

1. Prior cataract surgery or advanced cataract requiring combined surgery. Co-existing retinal diseases (e.g., diabetic retinopathy, retinal detachment, retinal vein occlusion).
2. Systemic conditions preventing safe surgery or follow-up.
3. History of prior ocular or periocular corticosteroid use, including intraocular injection, periocular injection, or long-term topical corticosteroid eye drops.

Where it's running

• Peking Union Medical College Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Weihong Yu, MD — Peking Union Medical College Hospital
• Study coordinator: Weihong Yu, MD
• Email: yuweihongpumch@163.com
• Phone: +8613671214306

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PathFinder 1.0 detects retinal abnormalities on macular OCT scans

  This study tests PathFinder 1.0's ability to find retinal issues on macular OCT scans in adults.

  Recruiting at 5 sites Carl Zeiss Meditec-Dublin CoCe · Tucson, Arizona and 5 other locations · NCT07680244

• Suprachoroidal triamcinolone for macular edema from non-infectious uveitis after failed sub-Tenon injections

  We will test whether a single suprachoroidal triamcinolone injection can improve vision and reduce central retinal swelling in people with macular edema from non-infectious uveitis who did not improve after sub-Tenon steroid injections.

  Recruiting Early Phase 1 University of Baghdad · Baghdad · NCT07145008

• Implanting functional intraocular lenses in patients with epiretinal membrane

  This study is testing whether a special type of eye lens can improve vision better than a standard lens for cataract patients with a specific eye condition.

  Recruiting at 2 sites Eye & ENT Hospital of Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT06719739

• Comparing immediate and delayed surgery for eye membrane issues

  This study is testing whether having eye surgery right away or waiting a bit longer helps people with vision problems from eye membrane issues see better.

  Recruiting at 49 sites Jaeb Center for Health Research · Scottsdale, Arizona and 48 other locations · NCT05145491

• Using advanced imaging technology during eye surgery

  This study is testing a new imaging technology during eye surgery to see if it can help doctors perform better and improve outcomes for patients with retinal diseases.

  Recruiting Duke University · Durham, North Carolina · NCT03713268

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.